School c?/'Mc~dicinr, Na.'as/ivillc. Tc~nnes.sc,c, 37232
the fusion glycoprotein of RSV, although the role of Ab-specific for the attachment glycoprotein of the homotypic subtype has not been defined (3) . Ab derived from pooled human sera or from RSV-immune cotton rats has been shown to effectively decrease RSV replication in cotton rat lungs when given intraperitoneally either before challenge (4) (5) (6) or after challenge with RSV (5) . Intraperitoneal administration of pooled human sera before challenge of cotton rats has an additive effect with that of ribavirin on decreasing RSV replication in lung (7) . Topical administration of RSV-specific antibody has also effectively decreased replication of RSV in the lungs of cotton rats (20) , as has transfer of maternal Ab in foster feeding experiments (4, 9) Treatment of RSV-infected owl monkeys with pooled human sera i.v. has also been shown to diminish RSV replication in lung wash samples (10) . RSV-specific MAb preparations have produced similar results in mice ( I I ) and cotton rats (12) . All studies have shown that RSV-immune serum preparations whether given parenterally or topically can decrease the replication of RSV in lung, and there has been no evidence of enhanced pathology in any of the model systems. However, RSV-immune Ab treatment has consistently diminished the Ab response to RSV challenge (5, 10) or vaccination ( 1 3, 14) . RSV-immune Abtreated cotton rats that underwent primary challenge with live RSV were protected from later rechallenge despite low Ab titers (5) . However, the diminished Ab response to RSV vaccination in cotton rats treated with RSV-immune Ab resulted in a greater susceptibility to subsequent challenge ( 13, 14) .
Studies of RSV immunoprophylaxis and immunotherapy in the cotton rat and owl monkey have been limited by the lack of RSV-induced illness. Nevertheless, because treatment with RSVimmune serum in animal models has shown diminished RSV replication in lung without enhancing lung pathology (5. 10). clinical trials of both immuno~ro~hvlaxis and immunotheraw have been initiated in children. in i n early trial of otherwjsk healthy infants with RSV lower respiratory tract disease, immunotherapy improved arterial Oz saturations but did not shorten length of hospitalization. There was no evidence of enhanced disease (15) . An uncontrolled pilot trial of immunoprophylaxis in high-risk children suggested that although RSV infection was not prevented, illness was mild in most cases (16) . Thus, passive immunoprophylaxis and immunotherapy may not only reduce viral shedding, but have the promise of reducing illness. For this study, we have used a reproducible illness model of RSV infection in BALB/c mice (I 7) to evaluate a specific human immune globulin with high titer of RSV neutralizing Ab (RSVIG) (18) that is currently being evaluated in clinical trials of RSV prophylaxis and treatment. Our experiments will provide the opportunity to validate the observations in the mouse system with those in children when the later data are analyzed. The murine model can potentially be used to anticipate success or problems with future products. The key difference between this and previous BALB/c mice resulted in a serum neutralization titer of 1 : 183 studies in animal models is our ability to measure illness end-within 2 h of administration. Mice were treated with a series of points and demonstrate lung pathology in RSV-infected animals. RSVIG dilutions 16 h before RSV challenge, then killed 72 h after challenge to measure RSV titer in lung and nose. The titer MATERIALS AND METHODS of RSV recovered from lung and nose was inversely proportional to the amount of Ab administered and to the resulting serum Mice. Pathogen-free female BALB/c mice were purchased neutralizing Ab titer (Fig. 1) . Parenteral administration of from Charles River Laboratories (Raleigh. NC). Retired breeders RSVIG had a greater effect on the RSV titer in lung than in the (8 to 10 mo old) were used in all experiments. They were shipped nose.
in filtered crates and housed in a Duo-flo laminar flow unit (Lab Experimental design. Three time points for RSVlG treatment Products, Inc., Maywood, NJ) remote from the central animal were chosen relative to the time of RSV challenge. In the d 0 facility. Cages, bedding, food. and water were sterilized before group, mice were treated with Ab 2 h before RSV challenge. The use. Room temperature was maintained at 27'C. and a 12-h-on, d 1 group received treatment 24 h after RSV challenge, but 12-h-off light cycle was provided. In caring for animals, the before illness was apparent (i.e. during the incubation period). replication in lung and nose. Additional mice were killed on d 8 Ab. The Ab used for treatment (RSV Ig, lot no. 3, Massachu-to evaluate the effects on lung pathology. Another set of mice sens Public Health Biologic Laboratories, Jamaica Plains, MA) was observed throughout the recovery period after primary inis a human immune globulin prepared from the pooled plasma fection to evaluate illness parameters and RSV-specific Ab reof donors selected for high neutralizing Ab to RSV as previously sponses. This set of mice was rechallenged 1 mo after primary described (18) . After reconstitution from lyophilized powder, infection to determine their susceptibility to RSV reinfection. RSWG contains 50 mg of human immune globulin (>95% IgG) Untreated RSV-infected mice were killed at each time point as and 10 mg of albumin/mL. RSVIG was administered by intra-controls. peritoneal injection of a 200-pL suspension.
RSV replication after primary infection. Treatment of mice Cells and virus. Hep-2 cells were maintained in EMEM s u p before challenge (d O), after challenge and before onset of illness plemented with glutamine, amphotericin, gentamicin, penicillin (d I), or at the onset of illness (d 5) was effective in diminishing G, and 10% fetal bovine serum (10% EMEM). The A2 strain of RSV replication in lung. No virus was isolated from lung in any RSV was kindly provided by Dr. Robert Chanock, National of the RSVIG-treated mice (Table 1) . Nasal RSV replication was Institutes of Health. Working stocks of the virus were prepared also diminished, but not to the same extent. Mixing experiments as previously described (17) and maintained titers in the range demonstrated the presence of neutralizing activity in the lung of 10' plaque-forming units/mL for over 6 mo at -7O0C.
supernatants ofd 5-treated mice (Table 2) . One d after treatment, Mouse infection. Anesthetized mice were infected nasally with there was sufficient Ab in lung supernatants from treated mice 100 rL of undiluted stock virus as previously described (17) . A to diminish the number of plaques by more than 5-fold in the clinical illness grading scale was used to assign numbers to a set mixed cultures, presumably by in vitro neutralization or aggreof clinical features detected in mice with different degrees of gation of RSV in untreated lung supernatants. illness: 0, healthy; 1, barely mmed fur; 2, rumed fur, but active;
Illness and pathology after primary infection. RSV replication 3, rumed fur and inactive; 4, rumed fur, inactive, hunched, and was diminished in all RSVIG-treated groups, but only d 0-and gaunt; and 5, dead. Illness scores were assigned by a blinded d I-treated mice remained healthy (clinical score = 0). Even observer. Illness was also assessed by weighing the mice and though d 5-treated mice developed the same severity of peak measuring the core body temperature with a vaginal probe illness as the untreated controls as determined by weight loss, (Fisher Scientific, Norcross, GA). Mice were killed, and tissue clinical score, and temperature by d 8 after challenge (Table 11, samples were handled as previously described ( 17) . they had an earlier recovery than the untreated control group Viral quantitation and neutralization tests. Plaque assays for (Fig. 2) . Weight gain in the d 5-treated mice was significantly viral quantitation and plaque-reduction neutralization were per-greater than in the untreated controls at d 10 ( p = 0.01) and at formed as previously described ( 17) . To determine whether the d I I ( p = 0.02). Lung histology in d 0-and d 1 -treated mice reduction of RSV titers in lung could be an in vitro effect, a mixing experiment was performed. The supernatants from lungs harvested on d 6 from untreated mice and from mice that had sample were added to 0.8 mL of 10% EMEM, and 200 pL of > 6 -lung supernatant from a treated and untreated mouse were mixed 2 and added to 0.6 mL of 10% EMEM for plaque assays. ance of the assay has been described previously in detail (1 9) . 
RESULTS
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In vitro and in vivo neutralizing activity ofAb preparation. The (Fig. 3) .
Ah responscJ to primarjl RSV challenge. Mice treated with RSVIG on d 0 or d I did not have a detectable Ab response to RSV challenge when tested at d 28. Mice treated at d 5 had a mixed response with most having a low titer or no detectable RSV-specific Ab response, although one mouse in this group had a moderate titer of Ab to the F glycoprotein with no detectable neutralization Ab activity (Fig. 4) .
RSV replication qfier reinfection. Mice from each of the treatment groups were rechallenged on d 28 and killed 3 d later. There was significant RSV replication in the lungs of mice in the d 0 and d I RSVlG treatment groups, although less than that seen in primary RSV infection. In the d 5 treatment group. RSV replication in lung was reduced to a greater extent but was still detectable in all mice. There was no RSV detected in the lungs of untreated mice 3 d after rechallenge. The ability to isolate RSV from the lungs of rechallenged mice was inversely correlated with the Ab responses to primary RSV infection. RSV replication in nose after rechallenge was detected at low levels in the d 0 and d 1 treatment groups ( Table 3 ). The titer and frequency of RSV isolated from nose after rechallenge in d 0 and d 1 treatment groups, however, was significantly less than that seen in primary infection ( p < 0.001, two-tailed I test). The d 5 treatment group had no RSV isolated from nose after rechallenge.
Illness and pathologjv after reinfection. Mice were killed 3 d after rechallenge, and at that time all treatment groups were continuing to lose weight (Fig. 2) . Only the untreated group showed evidence of weight gain by d 3 after rechallenge. Illness based on the clinical score was modest in all treatment groups. but untreated mice appeared healthy (clinical score 0 ) after rechallenge. Therefore, mice treated with RSVlG developed a partial Ab response, remained susceptible to RSV reinfection, and experienced mild illness upon rechallenge. In contrast, untreated mice were completely protected from RSV reinfection and had no illness. The lung pathology correlated best with the serum Ab response. In mice treated on d 0 or d 1, there were virtually no lymphocytic aggregates in the peribronchovascular bundles present 3 d after rechallenge. Untreated mice had typical perivascular and peribronchiolar lymphocytic aggregates ( 19) . The mice treated on d 5 had lymphocytic aggregates in lung after rechallenge, but overall they were smaller than in the untreated controls (Fig. 5) . RSV immune serum for the prophylaxis or treatment of RSV infection include: 1 ) Can RSV re~lication be reduced? 2 ) Can was virtually normal, with only small numbers of lymphocytes RSV-induced illness be diminishkd? 3) Will immune serum surrounding the bronchovascular structures. Extensive lympho-cause enhanced illness? and 4) Will treatment blunt the immune cyte infiltration around bronchovascular structures and into response to RSV infection and leave the host more susceptible -
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to severe illness upon reinfection? Previous work in the cotton rat has shown reduced RSV replication after RSV immune serum treatment, but was limited by the lack of illness and pathology in the model system. The current study in a mouse model of RSV infection confirms many of the findings previously made in cotton rats but now adds observations about the role of RSVIG in affecting illness and pathology.
We have demonstrated that passively administered RSVIG effectively diminished the replication of RSV in mice whether used as preexposure prophylaxis, postexposure prophylaxis, or therapy. Limiting RSV replication will decrease direct virusinduced cytopathology, and decreasing viral antigen load should decrease the strength of the immune response, which is also a factor in the severity of illness (20, 2 1) .
The potential for in vitro neutralization of RSV by passive Ab in the lungs of RSV-immune serum-treated mice has not been noted in previous work examining passive Ab treatment of RSV in cotton rats (5) (6) (7) (8) . One factor may be that RSVlG has -5-fold higher neutralizing activity than standard i.v. immune globulin preparations used previously. I n vitro neutralization of RSV in these mixing experiments indicates the presence of residual anti-RSV activity in the lungs of treated mice and emphasizes the importance of illness endpoints in discriminating RSVIG effects in vivo. Decreased RSV in the lungs of mice treated with RSVIG on d 0 and d 1 closely paralleled reductions in RSV illness and pathology. We therefore believe that decreased virus recovery from RSV challenged animals reflects neutralization of virus before killing.
When treatment was initiated before the onset of illness, the severity of illness, Ab response, and lung pathology from primary Table 3 . RSV infection was markedly diminished. Serologic studies in infants (1, 2) and the reports of diminished pathology and decreased illness in colostrum-fed bovine RSV-infected calves (22) anticipated these results. If treatment was initiated at the first sign of illness (d 5), the maximal severity of illness was unchanged, but the duration of illness was shortened. Our observations have important implications for use of RSV-immune serum preparations in human subjects. Clearly, our results would predict that RSVIG administered prophylactically would offer the greatest protection against RSV lower respiratory tract illness. Nevertheless, even mice treated with RSVIG on d 5, a time of peak virus replication in lung, recovered more quickly than untreated mice. If the dynamics of pulmonary virus replication and immune response in mice and man are comparable, treatment with RSVIG after onset of pulmonary disease may therefore provide benefit. In the only pediatric trial reported to date, a standard human i.v. immune globulin, selected for relatively high neutralizing activity against RSV, had a modest impact on the overall severity of RSV-induced illness if begun after the onset of lower respiratory tract symptoms ( 15) . The mechanism by which RSVIG shortens duration of illness is not known. The decrease in RSV antigen might reduce activation of the immune system and thereby reduce the amount of immunopathology. Alternatively, Ab might directly modify the immune response and decrease immune-mediated disease. There is evidence in mice that passively acquired Ab can diminish the cytotoxic T cell response to RSV (23) .
There are potential differences in the action of human Ig in mice as compared with man because of altered Fc affinity for cells mediating antibody-dependent cell-mediated cytotoxicity or phagocytosis. Complement binding and activation may also be different than with species-specific Ig. There may also be a difference in the way cellular responses are modified in the presence of a nonmurine Ig. However. human instead of mouse Ig should not make a difference in direct neutralization of RSV, which is the dominant mechanism of Ig action in the cotton rat model of RSV (24) . Treatment of cotton rats with Fab fragments or treatment of complement-depleted cotton rats had no effect on protective efficacy (24) .
RSVIG treatment resulted in diminished RSV-specific Ab responses to primary RSV infection in the mice, and this correlated directly with the susceptibility to reinfection of lung upon rechallenge with RSV. Susceptibility to reinfection of lung after rechallenge in the setting of low or absent RSV-specific Ab has been previously demonstrated in mice ( 1 8, 25) . Diminished Ab response to RSV antigens in the presence of passively acquired Ab has been demonstrated in several systems (5, 10, 13, 14) . but in owl monkeys (10) and cotton rats (5) this did not effect susceptibility to reinfection as it did in our system. This may relate to differences in amount of RSV in the challenge inocula. the potency of the RSV immune sera used for treatment. or features of the experimental design or model system. Whereas RSVIG treatment increased the susceptibility of lung to reinfection, replication of RSV in nose after rechallenge was attenuated even in the RSVIG-treated mice (Table 3 ). In man. lung inoculation with RSV is probably the consequence of aspirating RSVladen nasal secretions. In contrast, the mouse model requires direct inoculation of lung to achieve lower respiratory tract infection. Evidence of nasal immunity to reinfection despite RSVIG treatment may therefore indicate that man might be less susceptible to subsequent lower respiratory tract infection after RSVIG treatment than predicted by the mouse model. RSVIG treatment decreased the lymphocytic infiltrate after rechallenge. Decreased size of the lymphocytic infiltrates and reduced serum Ab response were correlated with increased susceptibility to lung reinfection. The correlation of protection from lung reinfection with the presence of lymphocytic aggregates in lung and presence of RSV-specific serum Ab has also been seen in previous studies (19. 2 1). Even though illness after rechallenge was more apparent in RSVIG-treated mice, the illness compared with primary infection was attenuated. Because most severe illness is typically seen in infants infected with RSV in the first year of life, susceptibility to reinfection may not prove critical in guiding strategies of intervention. Rather, the ability of an RSVimmune serum preparation to delay RSV infection beyond the first year of life may significantly reduce morbidity.
In summary, we have evaluated a human RSVIG preparation in mice that is being concurrently tested in infants for immunoprophylaxis and immunotherapy. The human trial will ultimately allow direct evaluation of the model's validity for predicting the outcome of future clinical trials. The current study has shown that preexposure prophylaxis and immediate postexposure prophylaxis of RSV-infected mice reduces RSV replication in lung and illness during primary infection but decreases the RSV-specific Ab response. This results in susceptibility to reinfection of lung associated with mild illness. Immunotherapy of RSV-infected mice at the time illness is first apparent results in earlier recovery from illness even though peak RSV titers in lung and maximal illness are no different than in untreated controls. These data support continued evaluation of the use of RSVIG in clinical trials and exploration of new Ab formulations and methods for delivery in this mouse model of RSV infection.
